Zevra Therapeutics Sees Significant Rise in Short Interest and Analyst Optimism

Zevra Therapeutics Inc. (NASDAQ:ZVRA) Experiences Surge in Short Selling Activity In July, Zevra Therapeutics Inc. saw a notable increase in short interest. As of mid-July, short positions totaled approximately 4.9 million shares, representing a remarkable 166.3% rise from the end of June's 1.84 million shares. Currently, about 9.1% of the company's shares are sold short. With an average daily trading volume of 821,300 shares, investors have a short-term coverage horizon of around six days. Institutional investors and hedge funds have actively adjusted their stakes in ZVRA. Notably, BNP Paribas Financial Markets initiated a new position worth around $53,000 in Q4. GAMMA Investing LLC increased its holdings by over 20,500% in Q1, now owning 8,059 shares valued at $60,000. Strs Ohio entered with a new investment of approximately $125,000, while Squarepoint Ops LLC increased its shares by 36.1%, holding 16,534 shares valued at $138,000. ProShare Advisors LLC also took a new position worth about $145,000 in Q4. Overall, institutional investors hold roughly 35% of the company's stock. Analyst assessments remain optimistic. Citigroup reaffirmed an "outperform" rating in May. Cantor Fi...